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Major depressive disorder is a disabling psychiatric condition that causes a signiﬁcant burden on in-
dividuals and society. There is still a lack of a clear understanding of the neuropathological changes
associated with this illness and the efﬁcacy of antidepressants is still far from optimal. Research into
antidepressant therapies has evolved from serendipitous observation in human trials, but more than 60
years after the ﬁrst monoaminergic antidepressants emerged they remain the mainstay for treating
depression. However, glutamatergic modulators such as ketamine became the forefront of anti-
depressant exploration, especially for treatment-resistant depression and suicidal ideation. The gluta-
matergic hypothesis of depression is not new, however other NMDA receptor modulators do not seem to
share the rapid and sustained effects of ketamine, suggesting that a unique combination of intracellular
targets might be involved in its effect. Interestingly, inﬂammation can impact the glutamatergic system
enhancing excitotoxicity and decreasing neuroplasticity. The points of convergence between the in-
ﬂammatory and glutamatergic hypotheses of depression are not completely established, especially re-
garding the effects of fast-acting antidepressants. In this review, we discuss the most recent research
surrounding glutamatergic fast-acting antidepressants, capable of modulating cellular plasticity and
synaptogenesis and the potential of anti-inﬂammatory compounds evaluated from a different perspec-
tive. The combination of innovative ideas plus improvements on the discoveries made so far might lead
to advances in antidepressant research with the promise of ﬁnding compounds that are both effective
and fast-acting, even in patients who have tried other therapies with limited success.
& 2015 Elsevier B.V. All rights reserved.1. Major depressive disorder (MDD) – pathophysiology and
current antidepressant treatment
MDD causes profound socioeconomic burden and negative
impact on functioning and quality of life of patients (Papakostas
and Ionescu, 2015). Although there has been signiﬁcant research
directed towards understanding the biologic underpinnings of
MDD, there is not a complete consensus about the neurochemical
alterations present in depressive individuals. The monoamine
hypothesis of depression proposes that underactivity of mono-
amines may underlie the pathophysiology of this disorder
(Schildkraut, 1965). In addition, impairments on structural plasti-
city and cellular resilience associated with reduced levels of brain-
derived neurotrophic factor (BDNF) have been implicated in the
pathophysiology of MDD (Sen et al., 2008). Chronic antidepressant
treatment increases BDNF levels, particularly in the hippocampusues).and prefrontal cortex, leading to stimulation of intracellular sig-
naling pathways and consequent regulation of genes associated
with neuroplasticity and cell survival (Castrén and Rantamaki,
2010).
Inﬂammation has also emerged as an important etiologic fac-
tor, and thus a potential pharmacological target for MDD. Pro-in-
ﬂammatory cytokines are increased in depressed patients (Dowlati
et al., 2009) resulting in an imbalance in critical neuroactive
compounds and changes in brain structural and synaptic plasticity
(Dantzer and Walker, 2014). Interestingly, antidepressant therapy
may attenuate this inﬂammatory dysfunction in depressed in-
dividuals (Lanquillon et al., 2000). Moreover, neuroinﬂammation is
associated with increased extracellular glutamate levels, causing
neurotoxicity that contributes to depressive symptoms (Sanacora
et al., 2012).
Current antidepressant treatments are limited in both efﬁcacy
and tolerability. The drawbacks include delayed therapeutic onset
and side effects that reduce adhesion to treatment (Papakostas
and Ionescu, 2015). Approaches targeting new pathways have
been investigated and may represent a signiﬁcant improvement in
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glutamatergic system
Seminal work by Trullas and Skolnick (1990) was the ﬁrst re-
porting that NMDA receptor antagonists exhibit antidepressant
properties in preclinical models. After this observation, several
laboratories demonstrated that functional antagonists at multiple
NMDA receptor sites including ligands at glutamate, polyamine,
glycine, bivalent cations and ionophore recognition sites are efﬁ-
cacious in models of depression (Sanacora et al., 2012).
In the late 1990s reduction of NMDA receptor function was
recognized as a long-term adaptation associated with anti-
depressant effects (Skolnick, 1999). A promising clinical study by
Berman et al. (2000) showed that the non-competitive NMDA
receptor antagonist ketamine induced a rapid and persistent an-
tidepressant response in severe depressive patients. Evidence now
indicates that ketamine inhibits NMDA receptors on GABAergic
interneurons increasing glutamate release. The consequent acti-
vation of AMPA receptors causes depolarization of postsynaptic
neurons, leading to voltage-dependent calcium channel activation.
As a consequence, BDNF released from vesicles activates mTOR
signaling. Finally, translation of synaptic proteins in prefrontal
cortex, particularly those implicated in synaptogenesis, including
PSD-95, synapsin and GluA1 is the ﬁnal event associated with
ketamine’s rapid antidepressant effect (Li et al., 2010).
Although the discovery of ketamine for treating severe de-
pressed patients has represented a signiﬁcant advance in the ﬁeld,
its abuse liability and potential neurotoxicity upon repeated use
has led to the interest in the development of safer fast-acting
antidepressants (Abdallah et al., 2015). Considering that ketamine
modulates the glutamatergic system, there has been increasing
interest in targeting this system for the development of novel fast-
acting antidepressants.
Our research group has particular interest in antidepressant
effects afforded by some endogenous compounds that target the
glutamatergic system. Several compounds capable of modulating
glutamatergic neurotransmission exhibit antidepressant effects in
animal models, such as zinc (Manosso et al., 2015), magnesium
(Cardoso et al., 2009), agmatine (Neis et al., 2015), ascorbic acid
(Moretti et al., 2011), creatine (Cunha et al., 2015a) and guanosine
(Bettio et al., 2012). We showed that ascorbic acid, creatine and
guanosine exert antidepressant-like effects by inhibiting NMDA
receptors and activating mTOR signaling (Bettio et al., 2012, Cunha
et al., 2015a,b, Moretti et al., 2014). The hippocampal phosphor-
ylation of p70S6K, a downstream target to mTOR, and increased
levels of PSD-95 were already observed 1 hour after a single ad-
ministration of ascorbic acid or creatine in mice (Cunha et al.,
2015b, Moretti et al., 2014). Moreover, the mTOR inhibitor rapa-
mycin abolished the antidepressant-like effect of ascorbic acid,
creatine and guanosine in the tail suspension test (Bettio et al.,
2012, Cunha et al., 2015b, Moretti et al., 2014), suggesting that
mTOR activation may be a key event underlying the anti-
depressant effects of these compounds.
Although there is limited clinical evidence indicating the ben-
eﬁcial effects of these compounds for MDD, zinc supplementation
was effective in combination with conventional antidepressants
(Lai et al., 2012). Regarding magnesium, although it still remains to
be established if its administration elicits ketamine-like effects in
behavioral paradigms, it is reported that ketamine increases brain
magnesium levels (Murck, 2013). A randomized clinical trial
showed that magnesium was as effective as imipramine for
treating MDD in diabetics (Barragán-Rodríguez et al., 2008). The
antidepressant effect of agmatine was documented in a smallnumber of subjects (Shopsin, 2013) and ascorbic acid was effective
as adjuvant agent for MDD in pediatric patients (Amr et al., 2013).
Antidepressant effects of creatine supplementation were also re-
ported in depressive patients (Allen, 2012). However, there are no
clinical studies evaluating the mood effects of guanosine.
The antidepressant effects of other NMDA receptor antagonists
and glutamate-modulators such as MK-801, AP-7, RO25-6981,
amantadine, memantine, CP-101,606 (traxoprodil) and riluzole
were extensively studied in preclinical models (Dutta et al., 2015).
Most of these agents fail to afford rapid and sustained anti-
depressant effects (Dutta et al., 2015; Preskorn et al., 2008; Zarate
et al., 2004). Some promising results were observed with the low-
trapping NMDA channel blocker AZD6765, which elicits rapid, but
not sustained, antidepressant effects in treatment-resistant MDD
patients (Zarate et al., 2013). However, the intracellular pathways
involved in its effect are not established. Also, antidepressant-like
effect of the NMDA receptor glycine-site partial agonist GLYX-13
requires AMPA receptor and mTOR activation, similar to ketamine
(Lu et al., 2014). The antidepressant potential of GLYX-13 was
conﬁrmed in a clinical trial, and a fast (2 h) and sustained remis-
sion of depressive symptoms was observed without dissociative
effects (Moskal et al., 2014; Preskorn et al., 2015). CP-101,606, a
selective NR2B receptor antagonist, produced symptoms’ remis-
sion by day 5 in depressed patients unresponsive to paroxetine
(Preskorn et al., 2008). However, the intracellular pathways asso-
ciated with this effect need to be elucidated in preclinical studies.
Metabotropic glutamate receptor modulators and AMPA re-
ceptor potentiators also represent interesting targets in the search
for novel fast-acting antidepressant compounds. The blockade of
presynaptic mGluR2/3 receptors regulates glutamate release and
produces rapid behavioral responses that require activation of ei-
ther AMPA receptors or mTOR signaling (Dwyer et al., 2012).
Speciﬁcally, LY341495, an mGlu2/3 receptor antagonist, reduced
the time required for antidepressants to exert their effects by a
mechanism dependent on stimulation and expression of AMPA
receptors in prefrontal cortex (Matrisciano et al., 2005). Moreover,
preclinical studies have shown that AMPA potentiators LY392098
and LY451616 exhibit antidepressant effects associated with hip-
pocampal increases on BDNF and progenitor cell proliferation.
Also, the AMPAkine Ampalex elicited a rapid antidepressant effect
when compare to ﬂuoxetine (Knapp et al., 2002). Sleep depriva-
tion, which is capable of producing rapid antidepressant effects,
has similar effects on AMPA-mediated plasticity, suggesting that
rapid enhancement of synaptic plasticity might represent the ﬁnal
target for symptoms remission (Faraguna et al., 2008).
Despite similar properties of these compounds at NMDA neu-
rotransmission, their inability to replicate the fast, robust and
sustained antidepressant effect of ketamine may be due to doses,
pharmacokinetic differences, and activation of different in-
tracellular signaling pathways.3. Anti-inﬂammatory agents for the management of MDD
Depressive symptoms are commonly observed in patients with
inﬂammatory conditions (e.g. aging and obesity), inﬂammatory
diseases (e.g. atherosclerosis, congestive heart failure and rheu-
matoid arthritis), and in patients undergoing cytokine im-
munotherapy (Capuron and Dantzer, 2003). The presence of
asthma and arthritis was signiﬁcantly higher in depressed in-
dividuals (odds ratio (OR)¼1.53, 95% CI, 1.03–2.28; OR¼1.95, 95%
CI, 1.17–3.25, respectively). Heart attack and stroke were more
prevalent in depressed patients when compared to controls
(OR¼3.76, 95% CI, 1.95–7.27; OR¼2.83, 95% CI, 1.59–5.06, respec-
tively) (Kim et al., 2015). Diabetes mellitus is also more prevalent
in the depressed group (OR¼1.65, 95% CI, 0.93–2.92) and a meta-
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creases the risk for MDD (OR¼1.55, 95% CI, 1.22–1.98) (Kim et al.,
2015; Luppino et al., 2010). Notably, MDD is associated with per-
ipheral increase on pro-inﬂammatory cytokines, such as tumor-
necrosis factor-α (TNF-α) and interleukin-1β (Dowlati et al., 2009).
Collectively, these data suggest that the relationship between
MDD and inﬂammation is bidirectional and driven by immune
deregulation.
Depressed patients also show increased plasma ratio of ky-
nurenine to tryptophan as a consequence of excessive activation of
the enzyme indoleamine 2,3-dioxygenase (IDO) by pro-in-
ﬂammatory cytokines. IDO activation produces kynurenine that, in
turn, may be metabolized by perivascular macrophages and mi-
croglia to generate neuroactive glutamatergic compounds, such as
quinolinic acid, an NMDA receptor agonist, contributing to gluta-
matergic excitotoxicity (Dantzer and Walker, 2014). Therefore,
anti-inﬂammatory agents modulating pro-inﬂammatory cytokines
levels, IDO activity, microglial activation and consequently gluta-
matergic excitotoxicity may be promising agents for MDD
treatment.
Several anti-inﬂammatory strategies, such as minocycline,Glutama
Modula
Fig. 1. Potential strategies for the management of MDD targeting glutamatergic modula
glutamatergic agents, including ascorbic acid, creatine, zinc, guanosine, as well as mGluR
GLYX-13 which modulate the glutamatergic system may cause antidepressant effects. Th
proteins (such as PSD-95 and GluA1), leading to synaptogenesis. This mechanism is part
mentioned glutamatergic modulators. Furthermore, proinﬂammatory cytokines induce
metabolite quinolinic acid, an NMDA receptor agonist that mediates excitotoxicity. Ketam
cytokines, KYN and its metabolites. IDO inhibitors decrease KYN levels and microglial
derived neurotrophic factor; ERK¼extracellular signal-regulated kinase; HAAO¼3
NU¼kynureninase; KMO¼kynurenine 3-monooxygenase; MEK ¼ mitogen-activated
NMDAR¼N-methyl-D-aspartate receptor; PI3K¼phosphoinositide 3 kinase; TrkB¼tropmonoclonal antibodies (anti-TNF-α) and IDO inhibitor (1-methyl-
tryptophan) produce robust antidepressant-like effects in pre-
clinical models (Liu et al., 2015). Several studies have shown the
effect of the nonsteroidal anti-inﬂammatory drugs (NSAIDs)
acetylsalicylic acid and celecoxib as adjunctive antidepressant
agents (Rosenblat et al., 2014). A meta-analysis exploring 14 ran-
domized clinical trials concluded that NSAIDs and cytokine in-
hibitors reduce depressive symptoms as compared to placebo
(Köhler et al., 2014). However, the best evidence available on the
subject is for celecoxib. A recent meta-analysis showed that 4–6
weeks of treatment with celecoxib was associated with higher
response (OR¼6.6, 95% CI, 2.5–17.0) and higher remission rates
(OR¼6.6, 95% CI, 2.7–15.9) in medicated MDD patients (Far-
idhosseini et al., 2014). It is still not established if these beneﬁts
are limited to patients with increased peripheral inﬂammatory
markers and there are no data to support the use of celecoxib or
other NSAIDs in antidepressant-resistant patients.
Preclinical studies show that depressive behavior associated
with inﬂammatory conditions involves increased glutamate levels
in prefrontal cortex of mice (Martín-de-Saavedra et al., 2013). In
addition, increased levels of pro-inﬂammatory cytokines andtergic
tors
tion and inﬂammation. Several studies have suggested that the ketamine and some
2/3 antagonist LY341495, and NMDA receptor glycine site functional partial agonist
ese compounds may cause stimulation of mTOR activity and synthesis of synaptic
icularly well established for ketamine and remains to be investigated for the other
IDO activation, which in turn increase the levels of kynurenine (KYN) and its toxic
ine and other anti-inﬂammatory drugs may decrease the levels of pro-inﬂammatory
activation and exert antidepressant effects. Akt¼Protein kinase B; BDNF¼brain-
-hydroxyanthranilate 3,4-dioxygenase; IDO¼ indoleamine 2,3-dioxygenase; KY-
protein kinase kinase; mTORC1¼mammalian target of rapamycin complex 1;
omyosin receptor kinase B.
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free suicide attempters (Erhardt et al., 2013). It is proposed that
glutamatergic modulators may be useful for treating MDD asso-
ciated with inﬂammatory dysfunctions. Interestingly, ketamine
abrogated anhedonic behavior induced by lipopolysaccharide ad-
ministration (a model of neuroinﬂammation) via AMPA receptor
activation (Walker et al., 2013). Furthermore, ketamine presents
anti-inﬂammatory properties associated with antidepressant-like
proﬁle in rodents submitted to maternal deprivation (Réus et al.,
2015). Therefore, glutamatergic modulators may reduce neuroin-
ﬂammation, contributing to remission of depressive symptoms.4. General conclusions and future perspectives
Drugs targeting the glutamatergic system that elicit safe and
fast-acting antidepressant action as well as anti-inﬂammatory
agents might represent promising strategies for MDD (Fig. 1). Re-
garding this issue, studies conducted by our and other laboratories
shed light on the possibility that glutamatergic modulators such as
magnesium, zinc, guanosine, creatine, ascorbic acid, as well as
GLYX-13 and LY341495 should be further investigated for efﬁcacy
in MDD treatment. Of note, the search for fast-acting anti-
depressants able to counteract neuroinﬂammation and increase
neuroplasticity and cell survival might lead to a signiﬁcant ad-
vance in antidepressant ﬁeld. However, much work remains to be
done to completely understand the mechanisms underlying the
antidepressant effects of ketamine and other compounds capable
of modulating glutamatergic transmission and activating mTOR
signaling. Future challenge will be determining whether these
rapid-acting compounds can be used for routine treatment in
MDD and establish how to maintain prolonged therapeutic effects.
However, it should be noted that mTOR signaling stimulation may
have some risk since it is implicated in disease states in which
growth is deregulated and homeostasis is compromised, such as
cancer, metabolic diseases and aging (Zoncu et al., 2011). To ad-
dress these issues preclinical and clinical research need to work
together to achieve advances in understanding the different be-
havioral, biochemical and genetic dimensions that integrate this
complex disorder.Acknowledgments
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